

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and Hong Kong Securities Clearing Company Limited (“**HKSCC**”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated December 30, 2024 (the “**Prospectus**”) issued by BrainAurora Medical Technology Limited (脑动极光医疗科技有限公司) (the “**Company**”).

This announcement is for information purposes only and does not constitute an offer or an invitation to induce an offer by any person to acquire, purchase or subscribe for any securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Company and the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

This announcement does not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of Offer Shares in any jurisdiction in which such offer, solicitation or sales would be unlawful. This announcement is not for release, publication or distribution, directly or indirectly, in or into the United States or any other jurisdiction where such distribution is prohibited by law, nor is this announcement an offer for sale or solicitation to purchase or subscribe for securities in the United States or any other jurisdictions.

The Offer Shares have not been, and will not be, registered under the United States Securities Act of 1933, as amended from time to time (the “**U.S. Securities Act**”), or any applicable state securities laws and may not be offered, sold, pledged or transferred within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the U.S. Securities Act (the “**Regulation S**”), except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act. The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S. There will be no public offer of securities in the United States.

In connection with the Global Offering, China International Capital Corporation Hong Kong Securities Limited, as the stabilizing manager (the “**Stabilizing Manager**”), or any person acting for it, on behalf of the Underwriters, may over-allocate or effect short sales or any other stabilizing transactions with a view to stabilizing or maintaining the market price of the Offer Shares at a level higher than that which might otherwise prevail in the open market. However, there is no obligation on the Stabilizing Manager or any person acting for it to conduct any such stabilizing action. Such stabilizing activity, if commenced, will be done at the absolute discretion of the Stabilizing Manager and may be discontinued at any time. Such stabilization action, if commenced, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilising) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

Potential investors should be aware that stabilizing action by the Stabilizing Manager, or any person acting for it, is not permitted to support the price of the Shares for longer than the stabilizing period, which begins on the day on which trading of the Shares commences on the Hong Kong Stock Exchange and ends on the 30th day after the last day for the lodging of applications under the Hong Kong Public Offering. The stabilizing period is expected to end on Sunday, February 2, 2025. As a result, demand for the Shares, and their market price, may fall after the end of the stabilizing period.

Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall in their sole discretion be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting – Underwriting Arrangements – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date.



BrainAurora Medical Technology Limited
脑动极光医疗科技有限公司
(Incorporated in the Cayman Islands with limited liability)

GLOBAL OFFERING

Number of Offer Shares under the Global Offering	: 181,112,000 Shares
Number of Hong Kong Offer Shares	: 18,112,000 Shares
Number of International Offer Shares	: 163,000,000 Shares
Offer Price	: HK\$3.22 per Offer Share, plus brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.00565% and AFRC transaction levy of 0.00015% (payable in full on application in Hong Kong dollars and subject to refund)
Nominal value	: US\$0.0000001 per Share
Stock code	: 6681


*Joint Sponsors, Overall Coordinators, Joint Global Coordinators,
Joint Bookrunners and Joint Lead Managers*



Joint Bookrunners and Joint Lead Managers



FOSUN INTL SECURITIES



BrainAurora Medical Technology Limited (脑动极光医疗科技有限公司)
ANNOUNCEMENT OF ALLOTMENT RESULTS

Unless otherwise defined herein, capitalised terms used in this announcement shall have the same meanings as those defined in the prospectus dated December 30, 2024 (the “Prospectus”) issued by BrainAurora Medical Technology Limited (脑动极光医疗科技有限公司) (the “Company”).

Warning: In view of high concentration of shareholding in a small number of Shareholders, Shareholders and prospective investors should be aware that the price of the Shares could move substantially even with a small number of Shares traded and should exercise extreme caution when dealing in the Shares.

SUMMARY

Company information

Stock code	6681
Stock short name	BRAINAUROA-B
Dealings commencement date	January 8, 2025*

*See note at the end of the announcement

Price Information

Final Offer Price	HK\$3.22
Offer Price Adjustment exercised	N/A

Offer Shares and Share Capital

Number of Offer Shares	181,112,000
Number of Offer Shares in Hong Kong Public Offering	18,112,000
Number of Offer Shares in the International Offering	163,000,000
Number of issued Shares upon Listing	1,266,278,000

Over-allocation

No. of Offer Shares over-allocated	0
---	---

The Overall Coordinators confirmed that there has been no over-allocation of the Offer Shares in the International Offering. Therefore, it is expected that the Over-allotment Option will not be exercised and the stock borrowing agreement will not be entered into for the purpose of covering over-allocations in the International Offering.

Proceeds

Gross proceeds (Note)	HK\$583.18 million
Less: Estimated listing expenses payable based on final Offer Price	HK\$(81.86) million
Net proceeds	HK\$501.32 million

Gross proceeds refers to the amount to which the Company is entitled to receive. For details of the use of proceeds, please refer to the section headed “Future Plans and Use of Proceeds” in the Prospectus.

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

No. of valid applications	10,891
No. of successful applications	7,468
Subscription level	11.39 times
Claw-back triggered	No
No. of Offer Shares initially available under the Hong Kong Public Offering	18,112,000
Final no. of Offer Shares under the Hong Kong Public Offering	18,112,000
% of final no. of Offer Shares under the Hong Kong Public Offering to the Global Offering	10.00%

For details of the final allocation of shares to the Hong Kong Public Offering, investors can refer to www.hkeipo.hk/iporesult to perform a search by name or identification number or www.hkeipo.hk/iporesult for the full list of allottees.

INTERNATIONAL OFFERING

No. of places	114
Subscription Level	1.01 times
No. of Offer Shares initially available under the International Offering	163,000,000
Final no. of Offer Shares under the International Offering	163,000,000
% of final no. of Offer Shares under the International Offering to the Global Offering	90.00%

The Directors confirm that, to the best of their knowledge, information and belief, save for a waiver from strict compliance with Rule 10.04 of and consent under paragraph 5(2) of Appendix F1 to the Listing Rules in respect of subscriptions of the Offer Shares by Mr. Huang Guangwei, an existing Shareholder, as cornerstone investor, (i) none of the Offer Shares subscribed by the places and the public have been financed directly or indirectly by the Company, any of the Directors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the places and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of Shares registered in his/her/its name or otherwise held by him/her/it.

The places in the International Offering include the following:

Cornerstone Investors

<i>Investor</i>	<i>No. of Offer Shares allocated</i>	<i>% of Offer Shares^(Note1)</i>	<i>% of total issued share capital after the Global Offering^(Note1)</i>	<i>Existing shareholders or their close associates</i>
Tasly (Hong Kong) Pharmaceutical Investment Limited (天士力(香港)醫藥投資有限公司)	12,074,000	6.67%	0.95%	No
Tasly (International) Healthcare Investment & Development Company Limited (天士力(國際)醫療健康投資發展有限公司)	24,148,000	13.33%	1.91%	No
Suzhou Ceyuan Fuhai Enterprise Management Partnership (Limited Partnership) (蘇州策源扶海企業管理合夥企業(有限合夥))	70,525,000	38.94%	5.57%	No
Huang Guangwei (黃光偉)	9,659,000	5.33%	0.76%	Yes
Subtotal	116,406,000	64.27%	9.19%	

Allottee with waiver/consent obtained

Investor	No. of Offer Shares allocated	% of Offer Shares^(Note1)	% of total issued share capital after the Global Offering^(Note1)	Relationship
Allottee with waiver from strict compliance with Rule 10.04 of and consent under paragraph 5(2) of Appendix F1 to the Listing Rules in respect of subscriptions of Offer Shares by an existing Shareholder as Cornerstone Investor^(Note2)				
Huang Guangwei (黃光偉)	9,659,000	5.33%	0.76%	A Cornerstone Investor and an existing Shareholder
Subtotal	9,659,000	5.33%	0.76%	

Notes:

1. The Over-allotment Option has not been exercised and will not be exercised.
2. Mr. Huang Guangwei (黃光偉) is a Cornerstone Investor and an existing Shareholder. The Stock Exchange has granted a waiver from strict compliance with Rule 10.04 of and consent under paragraph 5(2) of Appendix F1 to the Listing Rules in respect of subscriptions of Offer Shares by an existing Shareholder as Cornerstone Investor. For details, see the section headed “Waivers – Waiver from strict compliance with Rule 10.04 of and consent under paragraph 5(2) of Appendix F1 to the Listing Rules in respect of subscriptions of Offer Shares by an existing Shareholder as Cornerstone Investor” in the Prospectus and the section headed “Others / Additional Information – Placing to an existing shareholder as cornerstone investor with a waiver from the strict compliance with Rule 10.04 of the Listing Rules and a prior consent under paragraph 5(2) of Appendix F1 to the Listing Rules” in this announcement.

LOCK-UP UNDERTAKINGS

Controlling Shareholders

Name	Number of Shares held in the Company subject to lock-up undertakings upon Listing	% of shareholding in the Company subject to lock-up undertakings upon Listing	Last day subject to the lock-up undertakings^(Note 1)
ZTan Limited	275,468,000	21.75%	January 7, 2026
Wispirits Limited	109,052,000	8.61%	January 7, 2026
Wiseforward Limited	44,503,000	3.51%	January 7, 2026
Neurobright Limited	30,400,000	2.40%	January 7, 2026
Subtotal	459,423,000	36.28%	

Note:

1. The Controlling Shareholders will cease to be prohibited from disposing of or transferring Shares after the indicated date. Apart from the lock-up requirements under Rule 10.07 of the Listing Rules, the Controlling Shareholders has undertaken to the Joint Sponsors, the Overall Coordinators and the Company that, save for certain special circumstances, they will not, and will procure that no company or legal entity controlled by them or any nominee or trustee holding in trust for them will, at any time during the period ending on, and including, the date falling twelve months after the Listing Date, dispose of, nor enter into any agreement to dispose of or otherwise create any options, rights, interests or encumbrances in respect of, any of the Shares held by it on the date of the Prospectus. For details, see the section headed “History, Reorganization and Corporate Structure - Lock-Up Arrangements” and “Underwriting - Underwriting Arrangements - Hong Kong Public Offering - Undertakings by the Controlling Shareholders” in the Prospectus.

Existing Shareholders

<i>Name</i>	<i>Number of shares held in the Company subject to lock-up undertakings upon Listing</i>	<i>% of shareholding in the Company subject to lock-up undertakings upon Listing</i>	<i>Last day subject to the lock-up undertakings^(Note 1)</i>
Northern Light Strategic Fund IV L.P.	9,514,000	0.75%	January 7, 2026
Northern Light Venture Fund IV L.P.	115,729,000	9.14%	January 7, 2026
Northern Light Partners Fund IV L.P.	1,611,000	0.13%	January 7, 2026
Crusky Limited	123,527,000	9.76%	January 7, 2026
Healthblooming Limited	99,104,000	7.83%	January 7, 2026
Wisdomspirit Holding Limited	85,166,000	6.73%	January 7, 2026
China Frontier Capital Holding Limited (中國方大資本控股有限公司)	70,143,000	5.54%	January 7, 2026
Integriness Limited	40,327,000	3.18%	January 7, 2026
CICC Healthcare Investment Fund, L.P.	19,444,000	1.54%	January 7, 2026
Beijing Pegasus Travel Star Enterprise Management Center (Limited Partnership) (北京飛馬旅之星企業管理中心(有限合夥))	17,209,000	1.36%	January 7, 2026
Shenzhen Fengrui Dingxing Equity Investment Fund Partnership (Limited Partnership) (深圳豐瑞鼎興股權投資基金合夥企業(有限合夥))	14,144,000	1.12%	January 7, 2026
Anji Shundian Limited	11,150,000	0.88%	January 7, 2026
Ambertech Limited	7,502,000	0.59%	January 7, 2026
Huang Guangwei (黃光偉)	7,502,000	0.59%	January 7, 2026

Jenny Wang Limited	3,671,000	0.29%	January 7, 2026
Subtotal	625,743,000	49.42%	

Note:

- Each of the existing Shareholders of the Company will cease to be prohibited from disposing of or transferring Shares after the indicated date. Each of the existing Shareholders has entered into a deed of lock-up undertaking in favor of the Joint Sponsors, the Overall Coordinators and the Company imposing certain restrictions on dealings with their respective Shares. Pursuant to the deed of lock-up undertaking, save for certain special circumstances, each of the existing Shareholders undertakes that, inter alia, it/he will not, and will procure that no company or legal entity controlled by it/him or any nominee or trustee holding in trust for it/him will, at any time during the period ending on, and including, the date falling twelve months after the Listing Date, dispose of, nor enter into any agreement to dispose of or otherwise create any options, rights, interests or encumbrances in respect of, any of the Shares held by it/him on the date of the Prospectus. For details, see the section headed "Underwriting - Underwriting Arrangements - Hong Kong Public Offering - Undertakings by existing Shareholders" in the Prospectus.

Cornerstone Investors

Name	Number of shares held in the Company subject to lock-up undertakings upon Listing	% of shareholding in the Company subject to lock-up undertakings upon Listing	Last day subject to the lock-up undertakings ^(Note 1)
Tasly (Hong Kong) Pharmaceutical Investment Limited (天士力 (香港) 醫藥投資有限公司)	12,074,000	0.95%	July 7, 2025
Tasly (International) Healthcare Investment&Development Company Limited (天士力 (國際)醫療健康投資發展有限公司)	24,148,000	1.91%	July 7, 2025
Suzhou Ceyuan Fuhai Enterprise Management Partnership (Limited Partnership) (蘇州策源扶海企業管理合夥企業 (有限合伙))	70,525,000	5.57%	July 7, 2025
Huang Guangwei (黃光偉) ^(Note 2)	9,659,000	0.76%	July 7, 2025
Subtotal	116,406,000	9.19%	

Notes:

- In accordance with the respective Cornerstone Investment Agreement, the required lock-up ends on July 7, 2025. The Cornerstone Investors will cease to be prohibited from disposing of or transferring the Shares subscribed for pursuant to their respective Cornerstone Investment Agreement after the indicated date.

2. *Mr. Huang Guangwei (黃光偉) is an existing Shareholder of the Company. For further details, see the section headed “Waivers – Waiver from strict compliance with Rule 10.04 of and consent under paragraph 5(2) of Appendix F1 to the Listing Rules in respect of subscriptions of Offer Shares by an existing Shareholder as Cornerstone Investor” in the Prospectus and the section headed “Others / Additional Information – Placing to an existing shareholder as cornerstone investor with a waiver from the strict compliance with Rule 10.04 of the Listing Rules and a prior consent under paragraph 5(2) of Appendix F1 to the Listing Rules” in this announcement. Shares subscribed by Mr. Huang Guangwei (黃光偉) as a cornerstone investor are subject to lock-up undertaking as indicated above.*

PLACEE CONCENTRATION ANALYSIS

Placees*	Number of Shares allocated	Allocation as % of International Offering	Allocation as % of total Offer Shares	Number of Shares held upon Listing	% of total issued share capital upon Listing
Top 1	70,525,000	43.27%	38.94%	70,525,000	5.57%
Top 5	151,226,000	92.78%	83.50%	158,728,000	12.54%
Top 10	162,777,000	99.86%	89.88%	170,279,000	13.45%
Top 25	162,911,000	99.95%	89.95%	170,413,000	13.46%

Note:

* Ranking of placees is based on the number of Shares allotted to the placees.

SHAREHOLDERS CONCENTRATION ANALYSIS

Shareholders*	Number of Shares allocated	Allotment as % of International Offering	Allotment as % of total Offer Shares	Number of Shares held upon Listing	% of total issued Shares capital upon Listing
Top 1	0	0.00%	0.00%	558,527,000	44.11%
Top 5	70,525,000	43.27%	38.94%	964,599,000	76.18%
Top 10	134,517,000	82.53%	74.27%	1,158,505,000	91.49%
Top 25	167,310,000	102.64%#	92.38%	1,252,476,000	98.91%

Notes:

* Ranking of Shareholders is based on the number of Shares held by the Shareholders upon Listing.

More than 100% as some Shareholders are allotted with Shares through the Hong Kong Public Offering.

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, 10,891 valid applications made by the public will be conditionally allocated on the basis set out below:

NO. OF SHARES APPLIED FOR	NO. OF VALID APPLICATIONS	BASIS OF ALLOTMENT / BALLOT	APPROXIMATE PERCENTAGE ALLOTTED OF THE TOTAL NO. OF SHARES APPLIED FOR
		Pool A	
1,000	5,285	2,643 out of 5,285 applicants to receive 1,000 Shares	50.01%
2,000	783	470 out of 783 applicants to receive 1,000 Shares	30.01%
3,000	1,153	813 out of 1,153 applicants to receive 1,000 Shares	23.50%
4,000	238	186 out of 238 applicants to receive 1,000 Shares	19.54%
5,000	372	313 out of 372 applicants to receive 1,000 Shares	16.83%
6,000	137	124 out of 137 applicants to receive 1,000 Shares	15.09%
7,000	62	59 out of 62 applicants to receive 1,000 Shares	13.59%
8,000	78	77 out of 78 applicants to receive 1,000 Shares	12.34%
9,000	46	1,000 Shares	11.11%
10,000	428	1,000 Shares plus 22 out of 428 applicants to receive an additional 1,000 Shares	10.51%
15,000	776	1,000 Shares plus 159 out of 776 applicants to receive an additional 1,000 Shares	8.03%
20,000	162	1,000 Shares plus 53 out of 162 applicants to receive an additional 1,000 Shares	6.64%
25,000	69	1,000 Shares plus 30 out of 69 applicants to receive an additional 1,000 Shares	5.74%
30,000	398	1,000 Shares plus 202 out of 398 applicants to receive an additional 1,000 Shares	5.03%
35,000	69	1,000 Shares plus 41 out of 69 applicants to receive an additional 1,000 Shares	4.55%
40,000	59	1,000 Shares plus 39 out of 59 applicants to receive an additional 1,000 Shares	4.15%
45,000	26	1,000 Shares plus 19 out of 26 applicants to receive an additional 1,000 Shares	3.85%
50,000	134	1,000 Shares plus 105 out of 134 applicants to receive an additional 1,000 Shares	3.57%

60,000	74	1,000 Shares plus 66 out of 74 applicants to receive an additional 1,000 Shares	3.15%
70,000	37	2,000 Shares	2.86%
80,000	49	2,000 Shares plus 4 out of 49 applicants to receive an additional 1,000 Shares	2.60%
90,000	45	2,000 Shares plus 9 out of 45 applicants to receive an additional 1,000 Shares	2.44%
100,000	239	2,000 Shares plus 84 out of 239 applicants to receive an additional 1,000 Shares	2.35%
200,000	68	2,000 Shares plus 54 out of 68 applicants to receive an additional 1,000 Shares	1.40%
300,000	22	3,000 Shares	1.00%
400,000	15	3,000 Shares plus 9 out of 15 applicants to receive an additional 1,000 Shares	0.90%
500,000	11	3,000 Shares plus 9 out of 11 applicants to receive an additional 1,000 Shares	0.76%
600,000	6	4,000 Shares	0.67%
700,000	3	4,000 Shares plus 1 out of 3 applicants to receive an additional 1,000 Shares	0.62%
800,000	4	4,000 Shares plus 2 out of 4 applicants to receive an additional 1,000 Shares	0.56%
1,000,000	30	5,000 Shares	0.50%
Total	10,878	Total number of Pool A successful applicants: 7,455	
Pool B			
2,000,000	8	504,000 Shares	25.20%
3,000,000	4	755,000 Shares	25.17%
8,000,000	1	2,004,000 Shares	25.05%
Total	13	Total number of Pool B successful applicants: 13	

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, except for the Listing Rules that have been waived and/or in respect of which consent has been obtained, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and Stock Exchange trading fee payable.

OTHERS / ADDITIONAL INFORMATION

Placing to an existing shareholder as cornerstone investor with a waiver from the strict compliance with Rule 10.04 of the Listing Rules and a prior consent under paragraph 5(2) of Appendix F1 to the Listing Rules

Our Company has applied to the Stock Exchange, and the Stock Exchange has granted, a waiver from the strict compliance with Rule 10.04 of the Listing Rules and a consent under paragraph 5(2) of Appendix F1 to the Listing Rules to permit our Company to allow Mr. Huang Guangwei (黃光偉), an existing shareholder, to participate in the Global Offering as a cornerstone investor. The allocation of Offer Shares to Mr. Huang Guangwei (黃光偉) is in compliance with all the conditions under the waiver/consent granted by the Stock Exchange. For further details of the allocations of Offer Shares to Mr. Huang Guangwei (黃光偉) as a cornerstone investor, see the section headed “Allotment Results Details – International Offering – Allottee with waiver/consent obtained” in this announcement.

DISCLAIMERS

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”). The securities may not be offered or sold in the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.

The Offer Shares are being offered and sold outside the United States in offshore transactions in reliance on Regulation S under the U.S. Securities Act.

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Shares thereby being offered.

** Potential investors of the Offer Shares should note that the Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall in their sole discretion be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed “Underwriting – Underwriting Arrangements – Hong Kong Public Offering – Grounds for Termination” in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be on January 8, 2025).*

PUBLIC FLOAT

Immediately following the completion of the Global Offering, an aggregate of 372,204,000 Shares or approximately 29.39% of the total issued share capital of the Company will be held in the public hands. Therefore, the number of Shares in the public hands represents no less than 25% of the total issued share capital of the Company, satisfying the minimum percentage requirement in compliance with Rule 8.08(1) of the Listing Rules.

The Directors confirm that, immediately following the completion of the Global Offering, (i) no placee will, individually, be placed more than 10% of the enlarged issued share capital of the Company immediately after the Global Offering; (ii) there will not be any new substantial Shareholder immediately after the Global Offering; (iii) the three largest public Shareholders do not hold more than 50% of the Shares held in the public hands at the time of the Listing in compliance with Rules 8.08(3) and 8.24 of the Listing Rules; and (iv) there will be at least 300 Shareholders at the time of the Listing in compliance with Rule 8.08(2) of the Listing Rules.

COMMENCEMENT OF DEALINGS

The Share certificates will only become valid evidence of title at 8:00 a.m. on Wednesday, January 8, 2025 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the paragraph headed “Underwriting – Underwriting Arrangements – Hong Kong Public Offering – Grounds for Termination” in the Prospectus has not been exercised. Investors who trade the Shares on the basis of publicly available allocation details prior to the receipt of Share certificates or prior to the Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Wednesday, January 8, 2025 (Hong Kong time), it is expected that dealings in the Shares on the Stock Exchange will commence at 9:00 a.m. on Wednesday, January 8, 2025 (Hong Kong time).

The Shares will be traded in board lots of 1,000 Shares each, and the stock code of the Shares will be 6681.

By order of the Board
BrainAurora Medical Technology Limited
Mr. Tan Zheng
Chairman and Executive Director

Hong Kong, January 7, 2025

As of the date of this announcement, the board of directors of the Company comprise: (i) Mr. Tan Zheng and Dr. Wang Xiaoyi as executive directors; (ii) Mr. Li Sirui, Ms. Li Mingqiu and Mr. Deng Feng as non-executive directors; and (iii) Mr. Lam Yiu Por, Dr. Duan Tao and Mr. Li Yuezhong as proposed independent non-executive directors.